314:
291:
31:
646:
490:(CSF-1R), respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo linifanib is effective orally in mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg).
733:
43:
518:
Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, et al. (April 2006). "Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor".
694:
555:"Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors"
383:
397:
713:
425:
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
687:
487:
718:
728:
464:
680:
417:
497:
human cells back into young ones (as measured by transcriptomic age), without turning them all the way back into undifferentiated
88:
64:
468:
498:
483:
190:
270:
460:
159:
309:
594:
Yang JH, Petty CA, Dixon-McDougall T, Lopez MV, Tyshkovskiy A, Maybury-Lewis S, et al. (July 2023).
259:
150:
286:
660:
105:
625:
576:
535:
239:
664:
179:
615:
607:
566:
527:
326:
114:
199:
657:
553:
Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, et al. (April 2006).
313:
290:
620:
595:
723:
653:
494:
707:
302:
139:
571:
554:
531:
30:
645:
359:
170:
629:
580:
539:
493:
The substance has been used as part of a chemical cocktail to turn old and
611:
22:
125:
479:
250:
219:
382:
373:
230:
472:
210:
596:"Chemically induced reprogramming to reverse cellular aging"
275:
668:
442:
478:
of 0.2, 2, 4, and 7 nM for human endothelial cells,
371:
358:
325:
320:
301:
269:
249:
229:
209:
189:
169:
158:
149:
124:
104:
79:
63:
58:
42:
37:
138:
459:) is a structurally novel, potent inhibitor of
405:Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4nc(N)c34)cc2)c1
113:
734:Antineoplastic and immunomodulating drug stubs
688:
8:
21:
695:
681:
312:
289:
178:
29:
619:
570:
198:
510:
422:
402:
285:
93:
303:
20:
258:
238:
7:
642:
640:
488:colony stimulating factor 1 receptor
218:
129:
667:. You can help Knowledge (XXG) by
465:vascular endothelial growth factor
96:1--3-(2-fluoro-5-methylphenyl)urea
14:
644:
346:
343:
337:
430:Key:MPVGZUGXCQEXTM-UHFFFAOYSA-N
714:Drugs not assigned an ATC code
469:platelet-derived growth factor
352:
331:
1:
572:10.1158/1535-7163.MCT-05-0359
559:Molecular Cancer Therapeutics
532:10.1158/1535-7163.MCT-05-0410
520:Molecular Cancer Therapeutics
750:
719:Tyrosine kinase inhibitors
639:
321:Chemical and physical data
729:Experimental cancer drugs
461:receptor tyrosine kinases
438:
413:
393:
84:
28:
612:10.18632/aging.204896
25:
480:PDGF receptor beta
676:
675:
606:(13): 5966–5989.
450:
449:
384:Interactive image
271:CompTox Dashboard
16:Chemical compound
741:
697:
690:
683:
658:immunomodulatory
648:
641:
634:
633:
623:
591:
585:
584:
574:
565:(4): 1007–1013.
550:
544:
543:
515:
446:
445:
386:
366:
354:
348:
345:
339:
333:
316:
305:
294:
293:
279:
277:
262:
242:
222:
202:
182:
162:
142:
132:
131:
117:
33:
26:
24:
749:
748:
744:
743:
742:
740:
739:
738:
704:
703:
702:
701:
638:
637:
593:
592:
588:
552:
551:
547:
526:(4): 995–1006.
517:
516:
512:
507:
476:
441:
439:
434:
431:
426:
421:
420:
409:
406:
401:
400:
389:
364:
351:
342:
336:
297:
273:
265:
245:
225:
205:
185:
165:
145:
128:
120:
100:
97:
92:
91:
75:
72:Investigational
54:
17:
12:
11:
5:
747:
745:
737:
736:
731:
726:
721:
716:
706:
705:
700:
699:
692:
685:
677:
674:
673:
654:antineoplastic
649:
636:
635:
586:
545:
509:
508:
506:
503:
474:
448:
447:
436:
435:
433:
432:
429:
427:
424:
416:
415:
414:
411:
410:
408:
407:
404:
396:
395:
394:
391:
390:
388:
387:
379:
377:
369:
368:
362:
356:
355:
349:
340:
334:
329:
323:
322:
318:
317:
307:
299:
298:
296:
295:
287:DTXSID40229834
282:
280:
267:
266:
264:
263:
255:
253:
247:
246:
244:
243:
235:
233:
227:
226:
224:
223:
215:
213:
207:
206:
204:
203:
195:
193:
187:
186:
184:
183:
175:
173:
167:
166:
164:
163:
155:
153:
147:
146:
144:
143:
135:
133:
122:
121:
119:
118:
110:
108:
102:
101:
99:
98:
95:
87:
86:
85:
82:
81:
77:
76:
74:
73:
69:
67:
61:
60:
56:
55:
53:
52:
48:
46:
40:
39:
35:
34:
15:
13:
10:
9:
6:
4:
3:
2:
746:
735:
732:
730:
727:
725:
722:
720:
717:
715:
712:
711:
709:
698:
693:
691:
686:
684:
679:
678:
672:
670:
666:
663:article is a
662:
659:
655:
650:
647:
643:
631:
627:
622:
617:
613:
609:
605:
601:
597:
590:
587:
582:
578:
573:
568:
564:
560:
556:
549:
546:
541:
537:
533:
529:
525:
521:
514:
511:
504:
502:
500:
496:
491:
489:
485:
481:
477:
470:
466:
462:
458:
454:
444:
437:
428:
423:
419:
412:
403:
399:
392:
385:
381:
380:
378:
375:
370:
363:
361:
357:
330:
328:
324:
319:
315:
311:
308:
306:
304:ECHA InfoCard
300:
292:
288:
284:
283:
281:
272:
268:
261:
257:
256:
254:
252:
248:
241:
237:
236:
234:
232:
228:
221:
217:
216:
214:
212:
208:
201:
197:
196:
194:
192:
188:
181:
177:
176:
174:
172:
168:
161:
157:
156:
154:
152:
148:
141:
137:
136:
134:
127:
123:
116:
112:
111:
109:
107:
103:
94:
90:
83:
78:
71:
70:
68:
66:
62:
57:
50:
49:
47:
45:
41:
38:Clinical data
36:
32:
27:
19:
669:expanding it
651:
603:
599:
589:
562:
558:
548:
523:
519:
513:
492:
471:(PDGF) with
456:
452:
451:
440:
260:ChEMBL223360
65:Legal status
59:Legal status
18:
482:(PDGFR-β),
467:(VEGF) and
367: g·mol
310:100.206.772
240:CHEBI:91435
115:796967-16-3
80:Identifiers
708:Categories
505:References
499:stem cells
372:3D model (
360:Molar mass
200:CO93X137CW
171:ChemSpider
151:IUPHAR/BPS
106:CAS Number
89:IUPAC name
495:senescent
453:Linifanib
23:Linifanib
630:37437248
621:10373966
581:16648572
540:16648571
443:(verify)
140:11485656
44:ATC code
463:(RTK),
457:ABT-869
365:324.339
327:Formula
180:9660475
126:PubChem
628:
618:
579:
538:
486:, and
398:SMILES
251:ChEMBL
220:D09635
724:Ureas
652:This
600:Aging
418:InChI
374:JSmol
231:ChEBI
665:stub
661:drug
626:PMID
577:PMID
536:PMID
211:KEGG
191:UNII
160:5657
51:None
656:or
616:PMC
608:doi
567:doi
528:doi
484:KDR
276:EPA
130:CID
710::
624:.
614:.
604:15
602:.
598:.
575:.
561:.
557:.
534:.
522:.
501:.
475:50
473:IC
341:15
335:17
696:e
689:t
682:v
671:.
632:.
610::
583:.
569::
563:5
542:.
530::
524:5
455:(
376:)
353:O
350:5
347:N
344:F
338:H
332:C
278:)
274:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
